Drugs / p53 SLP
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01639885 | Aug 2011 → Jan 2014 | ovarian cancer | Leiden University Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | p53 SLP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01639885 ↗ |
| Known as | p53 Synthetic Long Peptide | “Chemo-Immunotherapy, Gemcitabine With Pegylated Interferon Alpha-2b (Peg-Intron) With and Without p53 Synthetic Long Peptide (p53 SLP) Vaccine, for Patients With Platinum...” NCT01639885 ↗ |
| Modality | Vaccine | “p53 SLP vaccine” NCT01639885 ↗ |